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ABSTRACT
The aberrant epigenetic silencing of tumor suppressor genes (TSGs) plays a major 
role during carcinogenesis and regaining these dormant functions by engineering of 
sequence-specific epigenome editing tools offers a unique opportunity for targeted 
therapies. However, effectively normalizing the expression and regaining tumor 
suppressive functions of silenced TSGs by artificial transcription factors (ATFs) still 
remains a major challenge. Herein we describe novel combinatorial strategies for 
the potent reactivation of two class II TSGs, MASPIN and REPRIMO, in cell lines 
with varying epigenetic states, using the CRISPR/dCas9 associated system linked 
to a panel of effector domains (VP64, p300, VPR and SAM complex), as well as with 
protein-based ATFs, Zinc Fingers and TALEs. We found that co-delivery of multiple 
effector domains using a combination of CRISPR/dCas9 and TALEs or SAM complex 
maximized activation in highly methylated promoters. In particular, CRISPR/dCas9 
VPR with SAM upregulated MASPIN mRNA (22,145-fold change) in H157 lung cancer 
cells, with accompanying re-expression of MASPIN protein, which led to a concomitant 
inhibition of cell proliferation and induction of apoptotic cell death. Consistently, 
CRISPR/dCas9 VP64 with SAM upregulated REPRIMO (680-fold change), which led to 
phenotypic reprogramming in AGS gastric cancer cells. Altogether, our results outlined 
novel sequence-specific, combinatorial epigenome editing approaches to reactivate 
highly methylated TSGs as a promising therapy for cancer and other diseases.
INTRODUCTION
The aberrant epigenetic silencing of tumor 
suppressor genes (TSGs) plays a major role in driving 
both cancer initiation and tumor evolution. In contrast 
with class I TSGs, which are frequently associated with 
loss of function alterations, class II TSGs are solely 
downregulated by epigenetic mechanisms, such as DNA- 
and histone-posttranslational modifications, and thus are 
not altered at the genomic level [1]. The reversible nature 
of these epigenetic alterations offers unique opportunities 
for potential therapies. However, gene reactivation of 
silenced TSGs remains a challenge, as it must overcome 
the threshold necessary to regain gene function and 
achieve cancer cell phenotypic reprogramming [2]. 
Although epigenetic drugs (epidrugs) inhibiting the 
enzymes that induce and/or maintain this epigenetic state 
are clinically implemented for the treatment of several 
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cancers, these drugs have revealed a number of off target 
effects, which may lead to high toxicity and even poor 
outcomes [3–5]. Accordingly, there is a demand for highly 
selective activation strategies that are able to upregulate 
the expression of otherwise dormant genes.
In the recent years the molecular biology field has 
rapidly evolved to generate novel precision medicine 
strategies, generally referred as Artificial Transcription 
Factors (ATFs), for locus-specific manipulation of gene 
expression. These molecular tools make it possible to 
target an endogenous locus, reprogram the abnormally 
silenced epigenetic state and correct gene expression 
patterns, ultimately treating the disease from within 
using the cell’s innate genomic machinery [6, 7]. ATFs 
generally consist of a DNA-binding domain (DBD) 
engineered with an effector domain that modulates the 
transcriptional activity of a targeted regulatory region, 
such as a promoter or enhancer [8, 9]. To date, three types 
of ATFs have been developed: Zinc Fingers (ZFs) [10], 
Transcription Activator-Like Effectors (TALEs) [11], and 
the Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) system associated with the bacterial 
Cas9 protein [12].
Protein-based ATFs, such as ZFs and TALEs, 
comprise sequence-specific DBDs directly linked to 
the effector domain. ZF proteins are one of the most 
ubiquitous transcription factors found in nature and the 
first ATF platform developed for (epi)genome engineering 
[13–15]. However, work done by our group and others 
[16, 17] has shown that multi-modular ZF proteins 
have substantial off-target genome-wide effects [16]. To 
overcome these limitations, alternative modular protein 
scaffolds, known as TALEs [18, 19], have been developed 
[20–22]. Even though TALEs are highly specific [23, 
24] programmable DNA-binding proteins [25–28], the 
repetitive nature of their DBD has posed some concerns 
for their stability in vivo when transduced with viral 
vectors [29, 30].
In contrast to ZFs and TALEs, the recently 
developed CRISPR system is a programmable, DNA-
binding ribonucleoprotein [31, 32]. The platform utilizes 
the enzyme Cas9, derived from the immune system of 
bacteria (most commonly S. pyogenes), which has helicase 
activity and two nuclease sites [33]. Cas9 is directed to 
the target sequence by a chimeric single guide RNA 
(gRNA), which recognizes the genome by complementary 
base pairing [34]. Mutation of two key amino acids has 
generated a catalytically inactive, ‘deactivated’ Cas9 
(dCas9), which can be linked to different effector domains 
for gene expression regulation [35–38]. The simplicity of 
the design, potential high specificity and multiplexing 
capacities has positioned the CRISPR/dCas9 system as 
the current ATF of choice to modulate gene expression 
patterns. Various epigenetic effector domains have been 
recently developed to increase the potency of CRISPR/
dCas9 in activating targeted genes, such as p300 [39], an 
H3K9 acetylase core catalytic domain, and VPR [40], a 
complex made of VP64, p65 and Rta fused in tandem to 
the C-terminus of dCas9. In addition, a modified gRNA, 
that incorporates two MS2 RNA aptamers into exposed 
loops of the scaffold structure of the guide, resulted in 
the generation of the Synergistic Activation Mediator 
(SAM) complex, which improved the potency of the 
transactivation by binding p65 and HSF1 in an activation 
helper protein [41].
In this study, we explored the potential of CRISPR/
dCas9 system in conjunction with protein-based ATFs, ZF 
proteins and TALEs, to reactivate two dormant class II 
TSGs, and determined optimized combinatorial strategies 
able to functionally reactivate tumor suppression in 
cancer cell models. We focused first on mammary serine 
protease inhibitor, MASPIN [42, 43], as a proof-of-
concept TSG for which ZF proteins were generated able 
to partially reactivate the gene [44–50], in breast and 
lung malignancies [51–53]. In addition, we validated the 
capacity of the optimized ATF platforms to reactivate a 
novel TSG, tp53 dependent G2 arrest mediator candidate, 
REPRIMO [54–56], which has been proposed to have 
tumor suppressive functions in gastric [57, 58] and thyroid 
cancers among others [59]. We compared individual 
ATFs, as well as combinations of multiple platforms 
and effector domains, to re-activate their expression in 
several cell lines associated with distinct epigenetic states. 
We demonstrated the benefit of using multiple activator 
domains simultaneously to enhance activation in highly 
silenced cell lines. Moreover, the combinatorial effector 
domain strategy of the SAM complex proved to be the 
strongest activator in highly methylated promoter contexts. 
Our study shows that transiently transfected CRISPR/
dCas9 systems were able to induce potent re-activation of 
dormant TSGs in cancer cell lines, effectively regaining 
tumor suppressive functions. These findings suggest 
further applications of epigenetic reprogramming and (re)
gain-of-function studies in cancer and other diseases.
RESULTS
Systematic comparison of artificial transcription 
factors for activating a tumor suppressor gene
We assessed the capacity of three different 
molecular platforms, previously employed for genome 
and epigenome editing, to reactivate silenced genes. 
ZFs, TALEs and CRISPR/dCas9 were each C-terminally 
linked with the transcriptional activator VP64 (Figure 
1A). We chose the silenced tumor suppressor mammary 
serine protease inhibitor (MASPIN) as a paradigm of an 
epigenetically silenced gene, since we had previously 
shown this gene can be partially reactivated in cell lines 
bearing high levels of MASPIN DNA methylation by 6ZF 
proteins targeting the proximal promoter: ZF-97 and ZF-
126 [44–50]. To compare protein-based ATF backbones, 
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we designed and constructed TALEs targeting 20 bp 
perfectly overlapping the 18 bp bound by the ZFs with 
proven upregulation activity. Further, we generated four 
sgRNAs for CRISPR/dCas9 targeting the promoter region 
encompassing the ZF/TALE binding sites. The relative 
positions of all ATF binding sites within the promoter are 
shown in Figure 1B along with their corresponding target 
binding sequences (Supplementary Table S1).
We investigated the potential of these molecular 
tools in three different cell lines, MCF7, HEK293T and 
H157, all harboring silenced MASPIN protein expression, 
but with varying levels of MASPIN mRNA expression. 
Figure 1: Schematic diagram showing the structure of ATF platforms used, their binding sequences and position 
within the MASPIN proximal promoter. A. Structural models of ZF (yellow); TALE (purple); and CRISPR/dCas9 (green) with 
sgRNA (red). All platforms are shown fused to a VP64 effector domain (blue). B. Schematic representation of MASPIN proximal promoter 
illustrating ZF (yellow), TALE (purple) and sgRNA (green) binding sites. ZFs and TALEs share overlapping target regions. Protospacer 
adjacent motif (PAM) sequences of sgRNA guides are underlined and CpG dinucleotides are illustrated in red. TSS refers to transcription 
start site. C. Methylation status of the 13 CpG dinucleotides in the MASPIN promoter, within 200 bp upstream of the transcription start site, 
in un-transfected MCF7 (left), HEK293T (middle) and H157 (right) cells. Colored boxes indicate the various binding sites of ATFs with 
corresponding sequences for sgRNA-180, TALE-128, ZF-126, TALE-99, ZF-97 and sgRNA-76 (left to right).
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MCF7 cells had the highest MASPIN basal expression, 
approximately 14 times higher than HEK293T cells and 
258 times higher than H157 cells (Supplementary Figure 
S1). Consistent with their degree of gene silencing, MCF7 
cells had low CpG methylation frequency (2.9 ± 1.5% 
on average), whereas CpG dinucleotides were highly 
methylated in both HEK293T and H157 cells (89.4 ± 5.4% 
and 80.5 ± 14% on average, respectively, Figure 1C). 
The protein expression of each construct in the cells was 
similar across molecular platforms as assessed by flow 
cytometry by quantification of green fluorescent protein 
GFP C-terminally linked to each backbone, which ruled 
out differences in regulatory capacity due to differential 
construct expression in the cells (Supplementary Figure 
S2).
In a poorly methylated promoter context with 
moderate basal MASPIN expression (MCF7 cells) 
individual ATFs significantly increased mRNA expression 
at different levels, but not all were associated with protein 
re-expression as assessed by immunoblotting (Figure 
2A). TALE-99 VP64 alone or in combination with TALE-
128 VP64 were the strongest activators (31.28-fold and 
20.3-fold relative to control, respectively, p<0.0001). 
Consistently, we observed the highest protein expression 
in these conditions. In contrast, TALE-128 VP64 did 
not produce significant MASPIN upregulation (2.62-fold 
relative to control, p>0.05). While CRISPR/dCas9 VP64 
and ZF VP64 proteins (ZF-97, ZF-126 or a combination of 
both) induced a significant MASPIN mRNA upregulation 
(18.71-fold compared to 12.92-fold, 5.23-fold and 11.20-
fold relative to control, respectively, p<0.0001), only 
CRISPR/dCas9 VP64 was able to induce protein re-
expression.
In the context of a highly methylated promoter 
with silenced gene expression, such as in the HEK293T 
(Figure 2B) and H157 cell lines (Figure 2C), we 
observed that all ATFs individually, except TALE-
128, significantly up-regulated MASPIN (p<0.0001) at 
the mRNA level, but failed to translate into significant 
protein re-expression by immunoblotting. Like in MCF7 
cells, TALE-99 was the strongest single activator (99.65-
fold and 125.5-fold relative to control in HEK293T 
and H157 cells, respectively). The combination of both 
TALEs improved activation even further (320.26-fold 
and 236.2-fold relative to control in HEK293T and H157 
cells, respectively), even though TALE-128 alone did not 
produce any significant change in expression (0.81-fold 
and 2.7-fold relative to control in HEK293T and H157, 
respectively, p>0.05). Similarly, a combination of both 
ZFs significantly increased MASPIN activation compared 
to ZF-97 and ZF-126 when transfected separately (227.14-
fold compared to 31.86- and 33.70-fold relative to control 
in HEK293T cells, respectively, and 37.5-fold compared 
to 15.6-fold and 6.8-fold relative to control in H157 cells, 
respectively). Moreover, delivery of CRISPR/dCas9 VP64 
resulted only in moderate transcriptional upregulation 
(24.95-fold and 29.4-fold relative to control for HEK293T 
and H157, respectively, p<0.0001). Here again, individual 
ATFs platforms failed to translate into significant 
MASPIN expression by immunoblotting in both cell lines.
As expected, the delivery of either dCas9 without 
an activator domain (CRISPR/dCas9 No Effector), 
or CRISPR/dCas9 VP64 without any guide targeting 
MASPIN (Supplementary Figure S3), did not produce 
significant changes in MASPIN mRNA expression in 
HEK293T cells (p>0.05 across all conditions relative to 
control). This confirmed that CRISPR/dCas9 required 
sgRNAs to direct the effector domain to the desired target, 
and that the helicase/topoisomerase activity of dCas9 alone 
was not able to activate transcription in the absence of a 
transactivator, such as VP64. These results indicated that 
ATFs targeted on the same locus had different activating 
potential depending on the epigenetic background of 
the cell line. While ATFs in low methylated promoters 
reactivated tumor suppressor protein expression, in a 
highly methylated promoter with lower basal expression, 
they resulted in transcript upregulation yet this was 
insufficient to elicit protein expression.
In order to improve activation potential, we 
exploited novel activator domains designed to enhance 
the effectiveness of the CRISPR/dCas9 system observed 
by using VP64 alone. To this end, we employed more 
recently characterized activator effector domains in 
fusion with the CRISPR/dCas9, including the catalytic 
histone acetyltransferase core domain of the human 
E1A-associated protein p300 (CRISPR/dCas9 p300), an 
epigenetic modifying enzyme, and linked to dCas9 to 
increase H3K27 acetylation, an epigenetic mark associated 
with higher transcription activity [39]. In addition, we 
utilized a strong transactivator complex, VPR (CRISPR/
dCas9 VPR), composed of three effectors: VP64, p65 and 
Rta, linked in tandem to the C-terminus of dCas9 [40]. 
This construct combined the effect of multiple recruiters of 
the transcriptional machinery into one single complex and 
demonstrated a synergic cooperation which significantly 
improved VP64’s gene activation [40].
These CRISPR/dCas9 constructs were transiently 
transfected in the MCF7, HEK293T and H157 cells and 
their activation potential investigated as described above 
(Figure 3A–3C). CRISPR/dCas9 VPR greatly increased 
MASPIN mRNA expression in all cell lines (419.8-fold, 
728.75-fold and 433.0-fold relative to control in the MCF7, 
HEK293T and H157 cell lines, respectively, p<0.0001). 
In contrast, CRISPR/dCas9 p300 did not significantly 
upregulate MASPIN at either mRNA or protein level in 
MCF7 nor in H157 cells (2.5-fold and 10.2-fold relative 
to control, respectively, p>0.05). Interestingly, CRISPR/
dCas9 p300 was able to significantly upregulate gene 
expression in HEK293T cells (563.36-fold relative to 
control, p<0.0001). Protein expression was consistent 
with qRT-PCR data, and CRISPR/dCas9 VPR elicited the 
strongest protein upregulation in all cell lines. Overall, 
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Figure 2: Transient transfection of individual ATFs up-regulates MASPIN expression. Each platform was transfected in A. 
MCF7, B. HEK293T and C. H157 cell lines. Top panels: qRT-PCR showing MASPIN expression after transfection with various individual 
ATF platforms: CRISPR/dCas9 VP64 construct with a mix of four gRNAs (green bars), ZF VP64 constructs (yellow bars), and TALE VP64 
constructs (purple bars). ZF mix and TALE mix represent an equimolar mix of both ZFs or TALEs, respectively. All qRT-PCR data indicate 
the fold change in MASPIN transcription levels relative to cells transfected with empty vector (pcDNA3.1 backbone), normalized against 
GAPDH expression (error bars represent ± SEM, n=3). Statistical significance: one-way ANOVA, corrected for multiple comparisons using 
the Tukey HSD test, p<0.05 (*), p<0.01 (**) and p<0.001 (***). Bottom panels: Translation levels of MASPIN (42 kDa) and α-TUBULIN 
(50 kDa) as shown by a representative immunoblotting (n=2) for each cell line.
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Figure 3: Up-regulation of MASPIN expression by second-generation CRISPR/dCas9 p300 and VPR. A mix of four gRNAs 
with dCas9 VP64, dCas9 p300 or dCas9 VPR were transfected into A. MCF7, B. HEK293T and C. H157. Top panels: qRT-PCR data show fold 
change in MASPIN expression for CRISPR/dCas9 VP64 (green), CRISPR/dCas9 p300 (orange) and CRISPR/dCas9 VPR (red), relative to cells 
transfected with empty vector (pcDNA3.1 backbone), normalized against GAPDH expression (error bars represent ± SEM, n=3). Statistical 
significance: one-way ANOVA, corrected for multiple comparisons using the Tukey HSD test, p<0.001 (***). Translation levels of MASPIN 
(42 kDa) and α-TUBULIN (50 kDa) as shown by a representative immunoblotting (n=2) are shown for each cell line.
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CRISPR/dCas9 VPR significantly upregulated MASPIN 
with higher potency than the other activator domains 
tested. In addition, this construct elicited detectable 
MASPIN protein re-expression, albeit at higher levels in 
poorly methylated promoter contexts.
Combinatorial approach to maximize 
upregulation of silenced tumor suppressor genes
We next set out to investigate if we could further 
improve activation efficiency in highly methylated 
contexts with different ATF tools and effector domains 
by combining the CRISPR/dCas9 system with protein-
based ATFs. We reasoned that the helicase/topoisomerase 
activity of dCas9 could facilitate chromatin accessibility 
and act synergistically with protein-based DBDs (ZFs and 
TALEs) in the context of hyper-methylated promoters to 
enhance transcriptional upregulation.
We began with the combination of CRISPR/
dCas9 VP64 with both ZFs VP64 to determine if there 
was a pharmacological synergy between these ATFs 
in upregulating target gene expression (Figure 4A). To 
assess synergisms, we transfected different ratios of 
plasmid DNA into HEK293T cells, gradually decreasing 
the dose of CRISPR/dCas9 from 100% to 50% of the 
total amount of plasmid DNA transfected per condition, 
while simultaneously increasing the dose of both ZFs 
from 0% to 50% of the total amount of plasmid DNA 
transfected. As expected, we observed a dose-dependent 
increase in MASPIN mRNA levels when both ATFs 
were transfected separately. However, when transfected 
in combination, a strong synergistic effect in MASPIN 
upregulation was observed (up to 506.13-fold relative to 
control when combining 50% CRISPR/dCas9 and 50% 
ZFs). To determine the interaction between the CRISPR/
dCas9 and ZF constructs in reactivating TSG expression 
we used the Chou and Talalay method [60]. This method 
calculates a Combination Index (CI) based on the effect 
of a combination between both agents (CI < 1 being 
synergistic, CI > 1 antagonistic and CI = 1 additive). 
In these experiments we considered the maximum fold 
change reached in MASPIN mRNA expression as complete 
fraction affected, as previously described [46]. We found 
that the combination of both, ZFs and CRISPR/dCas9 was 
strongly synergistic (CI<0.3) and similarly, synergistic 
interactions were observed when each ZF was transfected 
with CRISPR/dCas9 as single agent (Supplementary 
Figure S4A).
We next determined pharmacological interactions 
between TALEs and CRISPR/dCas9 in enhancing gene 
expression (Figure 4B). When increasing amounts of 
TALEs and decreasing amounts of CRISPR/dCas9 
were transfected, we observed a similar pattern in the 
dose response to that reported with the ZFs. MASPIN 
activation increased when higher doses of individual ATFs 
were transfected. More interestingly, a strong synergistic 
effect in MASPIN upregulation was observed again using 
CRISPR/dCas9 VP64 in combination with TALEs VP64 
(up to 350.26-fold relative to control, when combining 
50% CRISPR/dCas9 and 50% TALEs). Consequently, we 
found that TALEs and CRISPR/dCas9 were also strongly 
synergistic across all doses tested (CI<0.3). However, 
when using TALEs as single agents, only TALE-99 
improved CRISPR/dCas9 activation of MASPIN mRNA 
upregulation (199.3-fold relative to control, p<0.0001, 
Supplementary Figure S4B).
Next, we investigated if the synergistic effect of ZFs 
or TALEs with CRISPR depended solely on the helicase/
topoisomerase activity of dCas9 and/or the presence of 
targeted sgRNAs to recruit VP64 in the promoter region. 
We found that co-transfection of either CRISPR/dCas9 
with no effector, or CRISPR/dCas9 VP64 without sgRNAs 
into HEK293T cells in combination with either ZFs 
(Supplementary Figure S4C) or TALEs (Supplementary 
Figure S4D) did not result in significant differences in 
mRNA expression compared to ZFs or TALEs transfected 
alone (individually or in combination, p>0.05). This 
indicated that the activation of a protein-based scaffold 
ATF was not improved by the helicase/topoisomerase 
activity of dCas9 in the absence of a transactivator. 
Moreover, the synergy between agents relied on sgRNAs 
to target multiple transactivators to the corresponding 
promoter.
Finally, we explored a combination of all three 
platforms (Figure 4C), transiently transfected into 
HEK293T cells in a ratio of 1:1:2 (ZFs/TALEs/CRISPR 
respectively). We found that co-transfecting all three 
platforms achieved the highest activation of MASPIN 
mRNA (1302.4-fold relative to control, p<0.0001) 
and protein re-expression. These results indicated that 
a combination of different protein-based molecular 
backbones enhanced the activation potential of CRISPR/
dCas9, creating an opportunity for utilizing each platform 
with unique activator strategies.
To maximize gene reactivation on highly 
methylated cell lines (HEK293T and H157), we 
transfected a panel of second-generation CRISPR/
dCas9 activator domains in combination with TALEs. 
In HEK293T cells (Figure 5A), we found that activation 
was significantly enhanced when using CRISPR/dCas9 
p300 or CRISPR/dCas9 VPR in combination with 
TALEs VP64 (1065.49-fold vs 563.36-fold relative to 
control, and 1685.21-fold vs 728.75-fold relative to 
control, when compared to CRISPR/dCas9 constructs 
alone, respectively, p<0.0001). Both combinations were 
significantly superior to the activation by TALEs alone 
(445.72-fold relative to control, p<0.0001). Protein 
levels showed a similar pattern of activation, with 
CRISPR/dCas9 VPR in combination with TALEs VP64 
achieving the highest protein expression compared to 
all other combinations tested. In H157 cells (Figure 5B) 
we observed a significant increase in relative MASPIN 
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Figure 4: Synergistic up-regulation of MASPIN expression by combinations of protein-based ATFs and CRISPR/
dCas9 VP64 in HEK293T cells. The Combination Index (CI) is plotted for CRISPR/dCas9 VP64 co-transfected with ZF mix A. 
or TALE mix B. considering the fold change of mRNA reactivation levels as fraction affected. Left panel: qRT-PCR showing MASPIN 
expression after transfection with varying ratios of CRISPR/dCas9 VP64 (with a mix of four gRNAs) and both ZFs or both TALEs, 
expressed as a percentage of the total plasmid DNA transfected. Right panel: Combination Index (CI) at each fraction affected, calculated 
according to the Chou and Talalay method. C. Up-regulation of MASPIN expression by a triple combination of ATF platforms. HEK293T 
cells were transfected with a mix of both ZFs VP64 and/or a mix of both TALEs VP64 and/or CRISPR/dCas9 VP64 (with four gRNAs). The 
platforms delivered in each condition are indicated in the figure at a ratio of 1:1:2, using pcDNA3.1 empty vector to complete total amount 
of plasmid DNA transfected. Top panel: qRT-PCR data showing MASPIN expression. Bottom panel: Translation levels of MASPIN (42 
kDa) and α-TUBULIN (50 kDa) as shown by immunoblotting (n=2). All qRT-PCR data indicate the fold change in MASPIN transcription 
levels relative to cells transfected with empty vector, normalized against GAPDH expression (error bars represent ± SEM, n=3). Statistical 
significance: one-way ANOVA, corrected for multiple comparisons using the Tukey HSD test (***, p<0.0001).
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Figure 5: Up-regulation of MASPIN expression by combinations of different CRISPR/dCas9 constructs and protein-
based DBD ATFs in highly methylated cell lines. CRISPR/dCas9 systems using VP64 (green), p300 (orange) or VPR (red) and 
a mix of four gRNAs were transfected alone or in combination with both TALEs VP64 (A – HEK293T cells and B – H157 cells). qRT-
PCR data indicate the fold change in MASPIN transcription levels relative to cells transfected with empty vector (pcDNA3.1 backbone), 
normalized against GAPDH expression (error bars represent ± SEM, n=3). Statistical significance: one-way ANOVA, corrected for 
multiple comparisons using the Tukey HSD test, p<0.05 (*), p<0.01 (**) and p<0.001 (***). Translation levels of MASPIN (42 kDa) and 
α-TUBULIN (50 kDa) as shown by a representative immunoblotting (n=2). The platforms delivered in each condition are indicated in the 
figure.
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mRNA levels in CRISPR/dCas9 VP64 or p300 cells 
co-transfected with TALEs (102.16-fold vs 11.41-fold 
relative to control, and 74.36-fold vs 7.28-fold relative 
to control, when compared to CRISPR/dCas9 constructs 
alone, respectively, p<0.0001). In contrast with VP64 
or p300, co-transfection of CRISPR/dCas9 VPR with 
TALEs did not significantly increase the activation of 
MASPIN (381.28-fold vs 310.04-fold relative to control, 
when compared to CRISPR/dCas9 VPR alone, p>0.05).
To further explore combinatorial delivery of multiple 
effector functions, we next investigated the activation 
potential of the CRISPR/dCas9 and SAM complex [41]. 
When co-transfected into HEK293T cells (Figure 6A), the 
SAM helper protein enhanced MASPIN activation for both 
CRISPR/dCas9 VP64 and VPR constructs (5,916-fold and 
6,477-fold relative to control, respectively, p<0.0001), but 
did not improve the effect of CRISPR/dCas9 p300 (p>0.05). 
Similarly, CRISPR/dCas9 VP64 and VPR activation was 
greatly enhanced in H157 cells by three orders of magnitude 
(21,640-fold and 22,145-fold relative to control, respectively, 
p<0.0001, Figure 6B), while CRISPR/dCas9 p300 activation 
was not enhanced by the addition of the SAM complex. 
MASPIN protein expression increased consistently with 
transcript upregulation in each cell line.
To correlate the extent of tumor suppression gene re-
expression with cancer cell phenotypic reprogramming, we 
processed H157 cells transfected with CRISPR/dCas9 VPR 
alone or in association with SAM complex, and evaluated 
the impact on cell viability, proliferation and apoptosis. 
Consistently with the degree of MASPIN reactivation we 
found that CRISPR/dCas9 VPR with SAM was the most 
potent combination and significantly decreased cell viability 
relative to control (Figure 6C, p<0.0001), followed by 
CRISPR/dCas9 VPR alone, which in turn had a significantly 
lower cell survival rate than the control condition (p<0.0001). 
Consistently, we observed a decrease in expression of the 
proliferative marker Ki67 after 72 hours post transfection 
(50% vs 88% of Ki67-positive cells with CRISPR/dCas9 
VPR + SAM compared to control, p<0.0001, Figure 6D). 
As expected from re-activation of MASPIN, an increase in 
cleaved caspase-3 staining by immunofluorescence validated 
induction of cell apoptosis associated with transfection of 
CRISPR/dCas9 VPR and SAM complex (10.22% vs 0.171% 
cleaved-caspase-3 positive cells compared to control, 
p<0.005, Figure 6E). In conclusion, these data suggested 
that a combinatorial approach to deliver multiple ATFs and 
effector domains maximized TSG re-expression, which 
correlated with functional tumor suppression and cancer cell 
phenotypic reprogramming.
Validation of activation strategies on a novel 
class II TSG REPRIMO
To extend and validate the previous findings in 
another gene context, we chose a gastric cancer class 
II TSG REPRIMO. We designed three TALEs and a 
set of four gRNAs targeted to the proximal promoter 
of REPRIMO (Figure 7A) and we first validated these 
constructs in a low-expressing REPRIMO cell line, the 
triple negative breast SUM159 line (Figure 7B). While 
CRISPR/dCas9 systems upregulated gene expression in 
varying degrees depending on the effector domains fused 
to dCas9 (24.7-, 20.3-, 162.6-fold relative to control 
using VP64, p300 or VPR, respectively, p<0.001), 
the mix of TALEs fused to VP64 did not upregulate 
significantly REPRIMO ‘s expression (9.7-fold relative 
to control, p>0.05). We next tested these constructs on a 
gastric cell line, AGS, which harbor a highly methylated 
REPRIMO promoter [55], and expressing very low basal 
levels of the endogenous gene. As it was observed in 
the case of MASPIN re-expression in H157 cells, AGS 
only showed a significant REPRIMO up-regulation 
with the CRISPR/dCas9 VPR construct (88.34-fold 
relative to control, p<0.0001, Figure 7C) whereas all the 
other individual ATFs tested failed to upregulate gene 
expression (p>0.05).
Next, we evaluated the ability of the protein-
based ATF, TALEs, in combination with CRISPR/
dCas9 systems in AGS cells to improve reactivation of 
gene expression. CRISPR/dCas9 VPR further increased 
REPRIMO expression in combination with activating 
TALEs (117.94-fold relative to control, p<0.0001, 
Figure 8A), but was not significantly higher than 
CRISPR/dCas9 VPR alone (p>0.05). Finally, we co-
transfected each individual CRISPR/dCas9 activating 
platforms (VP64/p300/VPR) with a set of gRNAs able 
to recruit the SAM complex (Figure 8B). We observed a 
significant enhancement of REPRIMO gene expression 
with both CRISPR/dCas9 VPR (110.44-fold relative to 
control, p<0.0001), and CRISPR/dCas9 VP64 (680.62-
fold relative to control, p<0.0001) in association with 
the SAM helper protein. Accordingly, CRISPR/dCas9 
VP64 with the SAM complex significantly inhibited 
gastric cancer cell viability as compared to empty vector 
and CRISPR/dCas9 VPR alone (p<0.0001, Figure 8C). 
A decrease in Ki67 positive cells (58% vs 83% Ki67-
positive cells compared to control, p<0.0001, Figure 
8D) and an increase in cleaved caspase3 positive 
cells (20.1% vs 4.2% cleaved-caspase-3 positive cells 
compared to control, p<0.0001, Figure 8E) demonstrated 
an inhibition of cell proliferation by induction of 
apoptosis associated with CRISPR/dCas9 VP64 with 
SAM.
In conclusion, the reactivation of two Class II 
TSGs suggested similar responses to epigenome editing 
platforms, which depended on the cell lines and DNA 
methylation states. CRISPR/dCas9 systems associated 
with the SAM complex consistently reactivated dormant 
TSGs in the cell lines with hypermethylated promoters. 
Further, the combination of activating TALEs and 
CRISPR/dCas9 platforms offers the possibility to 
incorporate mechanistically distinct epigenetic effector 
for the locus-specific reprogramming of the aberrant 
cancerous state.
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Figure 6: Maximizing activation of MASPIN expression using SAM complex correlates with phenotypic reprogramming. 
CRISPR/dCas9 systems, linked to VP64 (green), p300 (orange) or VPR (red) were transfected using a mix of four modified gRNAs 2.0 
in combination with the SAM complex MS2-p65-HSF1 helper proteins. HEK293T cells A. and H157 cells B. were transfected with or 
without the SAM complex for each effector domain fused to dCas9. qRT-PCR data indicate the fold change in MASPIN transcription 
levels relative to cells transfected with empty vector, normalized against GAPDH expression (error bars represent ± SEM, n=3). Statistical 
significance: one-way ANOVA, corrected for multiple comparisons using the Tukey HSD test, p<0.05 (*), p<0.01 (**) and p<0.0001 (***). 
Translation levels of MASPIN (42 kDa) and α-TUBULIN (50 kDa) as shown by a representative immunoblotting (n=2). C. Viability assay 
in H157 cells comparing three successful activation strategies using CRISPR/dCas9 VPR: alone (with a mix of four gRNAs, orange) or 
with the SAM complex (with a mix of four gRNAs 2.0, yellow), and compared to CRISPR/dCas9 No effector with non-specific gRNAs 
(empty vector, black). Data is shown in absolute luminescence (RLU) at 24, 48, 72 and 96 hours post transient transfection (error bars 
represent ± SEM, n=3), and comparison using t-student test with Welch’s correction was performed to compare cell viability at 96 hours 
(***, p<0.0001). Immunofluorescence detection of Ki67-positive cells D. and cleaved caspase3 E. to assess proliferation and apoptosis 
in cells 96 hours post transfection with CRISPR/dCas9 VPR with or without SAM helper protein. Quantification is shown as percentage 
of corresponding positive cells and a representative image of Hoechst staining (blue) and either Ki67 or CL-caspase3 (red) are provided. 
Statistical significance: Student’s t-test with Welch’s correction, p<0.001 (**) and p<0.0001 (***).
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Figure 7: Design and construction of gRNAs and TALEs to activate REPRIMO mRNA expression in silenced cell lines. 
A. Schematic representation of REPRIMO proximal promoter illustrating TALEs (purple) and gRNA (green) binding sites. TSS refers to 
transcription start site. qRT-PCR data showing REPRIMO expression after transient transfection of a combination of TALEs (purple) and 
CRISPR/dCas9 systems with a mix of four gRNAs (VP64 in green, p300 in orange and VPR in red) into SUM159 B. and AGS C. cells. 
Data indicate the fold change in REPRIMO transcription levels relative to cells transfected with empty vector, normalized against GAPDH 
expression (error bars represent ± SEM, n=3). Statistical significance: one-way ANOVA, corrected for multiple comparisons using the 
Tukey HSD test, p<0.01 (**) and p<0.0001 (***).
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Figure 8: Activation of novel TSG, REPRIMO, using CRISPR/dCas9 + SAM complex induces changes in cell 
proliferation. qRT-PCR data showing REPRIMO expression after transient transfection of CRISPR/dCas9 systems with a mix of four 
gRNAs (VP64 in green, p300 in orange and VPR in red) with or without a combination of TALEs A. or SAM complex (using a mix of 
four gRNAs 2.0) B. in AGS cells. Data indicate the fold change in REPRIMO transcription levels relative to cells transfected with empty 
vector (pcDNA3.1 backbone), normalized against GAPDH expression (error bars represent ± SEM, n=3). Statistical significance: one-way 
ANOVA, corrected for multiple comparisons using the Tukey HSD test, p<0.05 (*), p<0.01 (**) and p<0.0001 (***). C. Viability assay in 
AGS cells comparing three successful activation strategies using CRISPR/dCas9 VPR with four gRNAs (orange) or CRISPR/dCas9 VP64 
with SAM complex and four gRNAs 2.0 (yellow), compared to CRISPR/dCas9 No effector with non-specific gRNAs (as empty vector in 
black). Data is shown in absolute luminescence (RLU) at 24, 48, 72 and 96 hours post transient transfection (error bars represent ± SEM, 
n=3), and comparison using t-student test with Welch’s correction was performed to compare cell viability at 96 hours (***, p<0.0001). 
Immunofluorescence detection of Ki67-positive cells D. and cleaved caspase3 E. to assess proliferation and apoptosis in cells 96 hours 
post transfection with CRISPR/dCas9 VPR or CRISPR/dCas9 VP64 with SAM helper protein. Quantification is shown as percentage of 
corresponding positive cells and a representative image of Hoechst staining (blue) and either Ki67 or CL-caspase3 (red) are provided. 
Statistical significance: Student’s t-test with Welch’s correction, p<0.001 (**) and p<0.0001 (***).
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DISCUSSION
In this study, we have compared different epigenetic 
editing approaches involving combinations of CRISPR/
dCas9 with protein-based ATFs (ZFs and TALEs). We 
used this combinatorial strategy to deliver state-of-the-art 
activator domains to effectively normalize TSG expression 
in cancerous cells. We have compared the potency of the 
three major ATF activator platforms across multiple cell 
lines with different epigenetic states and established robust 
synergisms between genome editing tools. We validated 
the use of combinatorial strategies using novel activator 
domains for powerful gene activation in a proof of 
concept TSG MASPIN and in the context of a novel TSG, 
REPRIMO, which are both silenced by DNA methylation 
in aggressive tumor cells. In both cases we found that the 
VPR domain and the SAM complex consistently enhanced 
upregulation with higher potency over all the other 
approaches investigated. Moreover, we reported for the 
first time a phenotypic reprogramming using transiently 
transfected CRISPR/dCas9 systems to re-activate TSG 
epigenetically silenced in cancer cells.
Although much work has been invested in the 
development of new platforms for gene activation, there 
is a scarcity of information comparing the efficacy of 
all platforms available. This is particularly important 
for epigenetically silenced TSGs, which require high 
levels of gene re-activation to elicit physiological and 
phenotypic responses. Here, we first compared ZFs, 
TALEs, and CRISPR/dCas9, equally engineered with the 
VP64 activator domain fused in the C-terminus of each 
protein. Despite the differences in size and number of 
plasmid components co-transfected in these experiments 
it was possible to evaluate the relative potency of 
single platforms and define synergistic combinations 
in reactivating gene expression. These synergistic 
interactions made possible the delivery of minimal 
amount of platforms in the combinations maximizing gene 
reactivation while decreasing potential toxicity.
Based on our group previous experience with ZFs 
activators successfully activating MASPIN [45, 49], 
we designed CRISPR and TALEs to bind in the same 
proximal promoter region that was validated as a hotspot 
for regulating its expression. We found that protein-based 
ATFs such as TALEs, were generally more potent as single 
agents than the CRISPR/dCas9 system in reactivating 
gene expression in the cell lines tested. Furthermore, we 
found that in cell lines having an epigenetically silenced 
gene, protein-based ATFs were highly synergistic with 
CRISPR/dCas9, while in cell lines having basal levels 
of gene expression CRISPR/dCas9 or TALEs as single 
agents were generally the most effective tool for gene 
reactivation. Wider tiling of the promoter with more 
gRNAs or protein DBDs is frequently recommended 
to enhance activation [61–63], but we also observed 
that by binding different scaffolds, even to the same 
locations, we significantly increased the effectiveness of 
gene upregulation. The enhancement of gene expression 
observed with ZFs and TALEs could be explained by 
remodeling of local chromatin configuration induced by 
binding of one individual platform, facilitating the binding 
of the second ATF. More work is required to determine 
the precise mechanism by which these ATFs could induce 
alterations in chromatin.
In an effort to enhance activation of gene expression 
of a target gene, novel effector domains have been 
developed and engineered in fusion with the CRISPR/
dCas9 system. The classic activator domain VP64 recruits 
PC4, CBP/p300 and the SWI/SNF complex, while the 
alternative activator p65, a trans-activating subunit of 
NF-κB, present in VPR and SAM complex, recruits a 
different set of cofactors: AP-1, ATF/CREB and SP1. 
HSF1 is a novel activator from the human Heat-Shock 
Factor 1 (HSF1), and Rta (Replication and Transcription 
Activator) is also a potent activator domain, derived from 
the γ-herpesvirus family, that recruits cofactors involved in 
the immediate early transcription. On the other hand, p300 
enhance activation indirectly by epigenetic reprogramming 
of histone marks [64], increasing H3K27 acetylation, an 
epigenetic mark associated to higher transcription activity, 
which could explain lower activation of gene expression 
in relevant cancer cell lines that likely lack endogenous 
drivers of TSGs, in contrast with a normal-like cell such as 
HEK293T. In the case of unmethylated promoters, the use 
of direct activators such as CRISPR/dCas9 VPR yielded 
the highest levels of mRNA and protein over all the other 
combinations tested.
We and others have demonstrated that combining 
these molecular tools can increase activation of gene 
expression [61, 62]. In order to overcome several 
epigenetics mechanisms silencing a TSG in a cancer cell, 
we used a combinatorial approach of CRISPR/dCas9 
systems in addition to protein-based ATFs, in particular 
the use of TALEs was a strategy of choice based on their 
high specificity for target sequences. In addition, we 
exploited the SAM complex, which binds p65 and HSF1 
to modified gRNAs that incorporate MS2 RNA aptamers 
into the stemloop and second loop which remain exposed 
in the ternary dCas9 complex [41]. Importantly, the SAM 
complex enhanced gene re-activation several orders of 
magnitude over other strategies tested. Interestingly, 
dCas9 VPR failed to improve activation over dCas9 VP64 
when used together with the SAM complex, which could 
be explained by a possible conformational interference 
between large functional domains (VPR and SAM, 
VP64 being smaller in size) or by the fact that VP64 and 
SAM could recruit a set of non-overlapping and more 
effective co-activators present in the cells. Interestingly, 
the SAM complex failed to enhance or even inhibit p300 
activation in all cell lines analyzed. Taken together, 
these data emphasized the importance of using the 
appropriate gene editing toolbox that is tailored to the 
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cell line and epigenetic state of the cell, and confirmed 
the benefits of using multiple effectors to maximize gene 
expression for strongly silenced TSGs. More importantly, 
a phenotypic reprogramming was associated with higher 
levels of activation. Notably by using the SAM complex 
we observed a significant reduction in proliferation, 
diminished cell viability and increased apoptosis. Thus, 
we demonstrated a correlation between potent reactivation 
of TSG re-expression using transiently transfected ATFs 
and cell viability, proliferation and apoptosis.
Finally, the strategy validated in MASPIN as proof 
of concept was later extended in a novel TSG, REPRIMO. 
This gene is relevant in gastric cancer and the methylation 
status of its promoter has been proposed as an effective 
biomarker [57, 58, 65]. As a p53 dependent G2 arrest 
mediator, REPRIMO, has been demonstrated to have 
tumor suppressive functions when overexpressed [55, 
59], however, regain of function using ATFs has not been 
previously achieved. We observed a marked reduction in 
proliferation when re-activating gene expression using 
CRISPR/dCas9 VP64 with SAM complex in a hyper 
methylated gastric cell line, AGS [55]. Once again, the 
combinatorial approach presented has proven consistently 
useful to induce phenotypic changes in cancer cells 
targeting otherwise silenced TSGs.
In summary, we have shown unprecedented 
reactivation of highly methylated and silenced TSGs using 
CRISPR/dCas9 systems. By exploiting combinatorial 
strategies of platforms and effector domains, we 
upregulated endogenous expression of relevant genes 
to control proliferation and apoptosis in cancer, thus 
showing a phenotypic reprogramming via non-viral 
delivery of novel molecular tools for epigenome editing. 
Epigenetic modifying agents, such as DNA demethylating 
molecules [66] (e.g., the drug Decitabine [67], a 5-aza-
2′-deoxycytidine) or Histone deacetyltransferase’s 
inhibitors [68] (e.g., the potent inhibitor Suberoylanilide 
hydroxamic acid, SAHA), have shown positive clinical 
results on hematological cancer, as well as some solid 
tumors [5, 69]. However, the mechanisms are not fully 
understood and risks of adverse and unpredictable side 
effects are a concern due to the unspecific nature of these 
drugs [46, 70]. Here we proposed a more targeted strategy 
to modify the epigenetic and gene expression patterns of 
cancer cells to reprogram their naïve diseased phenotype. 
If successful, this strategy could overcome the toxicity 
associated with current drugs and collateral side effects 
due to genome-wide modifications, although efficient and 
non-toxic delivery methods still remain a challenge. In 
addition to testing novel alternatives to deliver CRISPR 
systems to cancer cells, the next step is to perform in vivo 
studies to determine the impact of waking up dormant 
TSGs in a growing tumor in animal models.
In conclusion, we have systematically compared 
some of the available ATF platforms for epigenome 
editing (ZFs, TALEs and CRISPR/dCas9) of two silenced 
tumor suppressor genes (MASPIN and REPRIMO) to 
induce potent reactivation of endogenous gene expression. 
Moreover, we observed that each cell line responded 
differently to a particular effector domain or combination 
of ATFs and that therefore the repertoire of platforms and 
effectors must be carefully optimized for each gene and 
epigenetic state of the cell line tested. In addition, we 
compared more recently characterized state-of-the-art 
activator domains, including p300, VPR and the SAM 
complex, investigating the potential to reactivate TSG 
expression as single platforms and in combinations with 
protein-based ATFs. More importantly, we showed that 
non-viral delivery of CRISPR/dCas9 systems, especially 
in combination with the SAM complex, produced a 
robust activation of target dormant TSGs and effectively 
awaken them, thus regaining their suppressive functions, 
as seen by a decrease in proliferation rates and increase 
in apoptosis. These findings provide proof of concept to 
exploit these technologies, CRISPR/dCas9 systems in 
particular, on other dormant TSGs, restoring their functions 
to reprogram a cancerous phenotype. Non-viral delivery of 
ATFs to modulate gene expression remains a challenge for 
an effective therapy in cancer patients, however, our study 
provides evidence for future applications of the CRISPR/
dCas9 technology as a transient, targeted and efficient tool 
to restore tumor suppressive functions of dormant genes 
in cancer cells.
MATERIALS AND METHODS
Artificial transcription factor constructs
ZF fused with effector domain VP64. ZF-97 and 
ZF-126 with VP64 have been described previously [45]. 
TALE fused with effector domain VP64. TALE-99 and 
TALE-128 with VP64 were designed to target the same 
sites as ZF-97 and ZF-126, respectively. Each TALE 
targets two more nucleotides than its corresponding ZF 
(a total of 20 nt) in order to start in the nearest thiamine 
nucleotide. The custom-designed sequence was engineered 
by Genecopoeia TALE-TF service.
CRISPR/dCas9 fused with effector domains VP64/
p300/VPR. All dCas9 constructs used an inactivated form 
of S. pyogenes Cas9 protein with two mutations in D10A 
and H840A. pcDNA3.1-dCas9-VP64 and pcDNA3.1-
dCas9-p300 (Addgene plasmid # 47107 and 61357, 
respectively) had a C-terminal fusion of VP64 domain 
or human p300 HAT core (aa 1048-1664) domain [39], 
respectively, driven by a CMV promoter, a gift from 
Charles Gersbach. The pcDNA-dCas9-No Effector is HA 
tagged at the C-terminus (Addgene plasmid # 47106). 
pcDNA-dCas9-VPR [40] with VP64, p65 and Rta fused 
to its C-terminus (Addgene plasmid 63798) was a gift 
from George Church. All dCas9 vectors used the same 
set of four sgRNAs based on the pSP-gRNA backbone 
vector (Addgene plasmid # 47108). Individual guides 
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were designed using the crispr.mit.edu website tool to find 
target sequences in MASPIN and REPRIMO proximal 
promoters (Supplementary Figure S1) and cloned into 
BbsI sites in the sgRNA expression vector, pSP-gRNA 
backbone, following Gersbach’s protocol [24].
Cell lines, cell culture and transfection
The HEK293T human embryonic kidney cell line 
was obtained from the American Type Culture Collection 
(ATCC, Manassas). The H157 human lung cancer cell 
line was kindly provided by Dr. Robert Winn (University 
of Colorado Health Science Center). Human breast 
cancer cell lines MCF7 and SUM159 were obtained 
from the Tissue Culture Facility of the UNC Lineberger 
Comprehensive Cancer Center (University of North 
Carolina, Chapel Hill). SUM159 cells were cultured in 
F12 media supplemented with 5% FBS, 5 μg/mL insulin, 
1 μg/mL hydrocortisone. MCF7 cells were cultured in 
MEM alpha media supplemented with 10% FBS and 1% 
each of sodium pyruvate, sodium bicarbonate and non-
essential amino acids. HEK293T cells were cultured in 
DMEM media supplemented with 10% FBS. H157 cells 
were cultured in RPMI 1640 supplemented with 5% FBS. 
All cells were cultured with 1% penicillin/streptomycin 
unless stated otherwise.
Transfections were performed in 6-well plates using 
Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s protocol. 5 x105 cells were seeded 24 
hours prior to transfection in their corresponding media, 
washed with PBS and cultured in Opti-MEM (750 μL). 
Each well was transfected using 4.8 μl of Lipofectamine 
2000 in 250 μL of Opti-MEM with 2.4 μg of total plasmid 
DNA, according to the manufacturer’s protocol. All 
transfections had the same total amount of plasmid DNA 
and pcDNA3.1 empty vector was added to complete the 
total amount of 2.4 μg per well. Genomic DNA, total RNA 
and protein were collected 48 hours post-transfection. The 
transfection efficiency of these combinations in H157 cells 
was between 40-50%, as assessed by flow cytometry of a 
control EGFP plasmid.
Methylation assay
Genomic DNA was obtained using QIAamp DNA 
Mini and Blood Mini Kit (Qiagen), as per manufacturer’s 
instructions, in wild type cells. All methylation assays 
were done by pyrosequencing designed using the 
algorithms built into the PyroMark Assay Design 
Software (Version 2.0.1, Qiagen). MASPIN primers 
sequences used are as follows: forward PCR primer, 
TGGATAAGTTGTTAAGAGGTTTGAGTAG, reverse 
PCR primer, 5′Biotin-ACTACCCCACCTTACTTACCTA, 
and sequencing primers, S1-GTTTGAGTAGGAGAGGA 
and S2-GTGTTGTTTAGGTGAGTTA. DNA samples 
were converted using the Epitect Bisulphite Conversion 
Kit (Qiagen). 500 ng of genomic DNA were converted 
overnight in 140 μL total volume using the standard 
protocol from the kit.
All PCR amplifications were performed with the 
PyroMark PCR Kit (Qiagen), as per manufacturer’s 
instructions. The PCR product was bound to Streptavidin 
Sepharose High Performance beads (GE Healthcare Life 
Sciences), the beads containing the immobilized PCR 
product were denatured and washed using proprietary 
solutions (Qiagen) on the Pyrosequencing Vacuum Prep 
Tool (Qiagen) to isolate a single stranded template. 
The beads were then transferred to an optically clear, 
24 well sequencing plate in 0.3 μM of pyrosequencing 
primer. Annealing to the single-stranded template was 
done by heating the plate to 80°C followed by cooling 
to room temperature. Pyrosequencing was performed on 
a PyroMark 24 Pyrosequencing System (Qiagen) as per 
the manufacturer’s instructions. Data was analyzed on the 
PyroMark Q24 software to give the %methylation values 
for each CpG site in the sample.
RNA extraction, cDNA conversion and relative 
qPCR
RNA was extracted from transfected cells 
using QIAzol Lysis Reagent (QIAGEN) according to 
manufacturer’s instructions, and 2 μg of purified total 
RNA was used as the template for cDNA synthesis 
using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). Relative quantification of 
transcript expression (MASPIN, REPRIMO and GAPDH) 
was obtained by quantitative real-time PCR (qRT-PCR) 
using commercially available fluorescent TaqMan 
probes (Applied Biosystems) in the ViiA 7 Real-Time 
PCR machine (Applied Biosystems), and analyzed 
using QuantStudio Real Time PCR Software (v1.1, 
Applied Biosystems). Data were analyzed according to 
MIQE guidelines [71] and results are expressed as fold 
change compared to empty vector transfected cells after 
normalization against GAPDH mRNA levels.
Western blotting
Cell lysates were collected using Cell Lysis 
Buffer 1x (Cell Signaling) supplemented with 1 mM 
PMSF and sonicated for 5 seconds at 10 mA. From 
each sample, 65 μg of protein was resolved by 10% 
SDS/PAGE (BioRad) and subsequently transferred to 
a PVDF membrane (BioRad). Immunoreactivity was 
determined with mouse anti-MASPIN (monoclonal, 1: 
1,000 dilution, Pharmingen) or with mouse anti-alpha-
TUBULIN (monoclonal, 1: 5,000 dilution, clone B512, 
Sigma-Aldritch) primary antibodies and goat anti-
MOUSE-HRP secondary antibody (1:10,000 dilution, GE 
Technology). Visualization was performed by enhanced 
chemiluminescence, Novex ECL Chemiluminescent 
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Substrate Reagent Kit (Invitrogen) with the ChemiDoc MP 
system (BioRad). All membrane pictures were digitally 
obtained in the ChemiDoc MP system and processed using 
ImageLab Software (v5.2, BioRad) and ImageJ.
Cell viability
Cell viability for H157 and AGS cells was 
assessed using CellTiter-Glo 2.0 Assay (Promega, NSW, 
Australia), according to the manufacturer’s protocol, and 
luminescence was measured using the EnVision 2102 
Multilabel Reader (PerkinElmer; Waltham, MA, USA). In 
brief, cells were seeded on a 6-well plate and transfected 
24 hours later using Lipofectamine 2000 (Invitrogen). 
After a 24 hours’ incubation, cells were collected using 
trypsin-EDTA 0.25% and seeded in 96-well plate wells 
(4 replicates plus one background control). Measurements 
were made at 24, 48, 72 and 96 hours’ intervals post 
transfection. Data (three biological replicates) were 
normalized to the average luminescence at 24 hours (first 
data point) and presented as luminescence RLU.
Immunofluorescence assay
Apoptosis and proliferation were assessed by 
immunofluorescence visualization of cleaved caspase-3 
(CL-caspase3) and Ki-67-positive cells, respectively, 
as previously described [72]. H157 and AGS cells were 
transfected in 6-well plates with different combinations 
of plasmids using Lipofectamine 2000 (Invitrogen) and 
collected 24 hours afterwards to be distributed in Lab-Tek 
Chamber slides system, 2x105 cells per chamber. After 
72 hours of transfection, cells were fixed with 4% para 
formaldehyde for 20 minutes, washed with PBS, blocked 
with blocking solution (5% fetal bovine serum, 0.3% 
Triton X-100 in PBS) for 1 hour, incubated with anti-CL 
caspase3 primary antibody (1:400 dilution; Cell Signaling 
Technology, QLD, Australia) or anti-Ki67 (1:400 dilution; 
Cell Signaling Technology, QLD, Australia) in blocking 
solution overnight and further incubated with an anti-rabbit 
or anti-mouse (for CL caspase3 or Ki67, respectively) 
secondary antibody Alexa Fluor 594-conjugated antibody 
(1:1000 dilution; Cell Signaling Technology, QLD, 
Australia) and Hoechst 33258 nucleic staining (1:10000 
dilution). The percentage of positive cells was determined 
by counting red fluorescent cells versus total cells using a 
fluorescent microscope (Olympus IX71).
Statistical analysis
Statistical analyses were performed with GraphPad 
Prism v6 (GraphPad Software Inc.) and Office Excel 365 
(Microsoft). Statistical significance was determined using 
an unpaired one-way ANOVA with the Tukey HSD post 
hoc test correcting for multiple comparisons for qRT-PCR 
data, or unpaired two sample Student’s t-tests (two-sided) 
for functional assays (viability, proliferation or apoptosis). 
For all tests, differences were considered significant at 
p<0.05 (*), p<0.001 (**) and p<0.0001 (***).
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